Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

790,916)Income tax benefit

--637,391998,408NET LOSS

$  (3,309,229)$ (4,236,381)$(12,815,929)$  (1,792,508)Basic and diluted net loss per common share

$
(0.09)$
(0.40)$
(0.64)$
(0.18)Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share

34,900,59110,722,06120,084,0229,861,215PALATIN TECHNOLOGIES, INC.

and SubsidiaryConsolidated Balance Sheets(unaudited)June 30, 2011June 30, 2010ASSETSCurrent assets:  Cash and cash equivalents$
8,869,639$
5,405,430  Available-for-sale investments-3,462,189  Accounts receivable131,1492,879  Prepaid expenses and other current assets261,947393,313Total current assets19,262,7359,263,811Property and equipment, net1,305,3312,388,365Restricted cash350,000475,000Other assets254,787261,701Total assets$
21,172,853$
2,388,877LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:  Capital lease obligations$
34,923$
9,670  Accounts payable 496,908155,795  Accrued expenses1,854,0072,219,466  Accrued expenses374,094-  Unearned revenue46,105-Total current liabilities2,806,0372,394,931Capital lease obligations 42,18614,284Deferred rent132,855661,389Total liabilities2,981,0783,070,604Stockholders' equity:  Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of June 30, 2011 and 2010, respectively5050  Common stock of $0.01 par value – authorized 100,000,000 shares; issued and outstanding 34,900,591 and 11,702,818 shares as of June 30, 2011 and 2010, respectively349,006117,028  Additional paid-in capital239,832,826218,236,723  Accumulated other comprehensive income-138,650  Accumulated deficit (221,990,107)(209,174,178)Total stockholders' equity18,191,7759,318,273Total liabilities and stockholders' equity$
21,172,853$
2,388,877
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Thornton Cleveleys (UK) (PRWEB) March 05, 2015 ... Enhanced implantable polymer have received the CE mark (European) ... within the European Free Trade Association (EFTA) and the ... CE mark has now been granted to implants supplied ... degenerative disc spinal conditions. , Osimplant's Cervical Expandable ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... USDM Life Sciences , a leading ... hired David Blewitt as Vice President of ... and Solutions at USDM Life Sciences , which help ... compliance with government regulations worldwide. , For more ... sciences regulatory and IS compliance professional with extensive hands-on ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... , , MINNEAPOLIS, Aug. 4 Techne ... has decided to pay a dividend of $0.25 per share for the ... August 31, 2009 to all common shareholders of record on August 17, ... Directors on a quarterly basis. , , Techne Corporation ...
... CRANBURY, N.J., Aug. 4 Palatin Technologies, Inc. (NYSE Amex: ... a Notice of Allowance from the U.S. Patent and Trademark ... Natriuretic Peptide Constructs." Allowed claims cover a family of ... including PL-3994, Palatin,s lead heart failure drug candidate. Palatin expects ...
... BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE AMEX: ... China, announced today,that the clinical trial of its A/H1N1 influenza ... shot of the vaccine and, during the,three day observation period, ... and reliable in humans. , The ...
Cached Biology Technology:Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 3Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 2Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 3
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:2/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ) ... Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, ... their offering. , In global ... anticipated to overtake North America ... towards IT security, government biometric based projects such ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... University of Illinois study, omega-3 fatty acids may be good ... implications for treating male infertility. "In our experiment, we ... enzyme important in making docosahexaenoic acid (DHA). In the absence ... any misshaped sperm that can,t get where they need to ...
... BLOOMINGTON, Ind. -- The world,s largest antimony mine ... environmental consequences of escaped antimony -- an element whose ... "Antimony is an emergent contaminant," said IU Bloomington ... have not paid enough attention to it." Used ...
... of Illinois scientists have learned that a specific omega-6 ... "In experiments with mice, we knocked out a ... to make arachidonic acid. Without arachidonic acid, the mice ... they scratched themselves continuously, and they developed a lot ...
Cached Biology News:U of I study: Lack of omega-3 fatty acid linked to male infertility 2A different kind of mine disaster 2A different kind of mine disaster 3U of I study: Lack of omega-6 fatty acid linked to severe dermatitis 2
... CE-based system provides clear advantages over ... load, gene expression), mutation analysis, and ... system with microplate connectivity is ideal ... quality control. The P/ACE Series ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... Kit is a 2-color staining method for ... to detect apoptotic cells by flow cytometry. ... required for measuring apoptosis in cells, including ... reagent performance; washing, reaction and rinsing buffers ...
Biology Products: